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Abstract
Background: As part of a clinical proteomics program focused on diabetes and its complications we are looking
for new and better protein biomarkers for diabetic nephropathy. The search for new and better biomarkers for
diabetic nephropathy has, with a few exceptions, previously focused on either hypothesis-driven studies or urinary
based investigations. To date only two studies have investigated the proteome of blood in search for new
biomarkers, and these studies were conducted in sera from patients with type 2 diabetes. This is the first reported
in depth proteomic study where plasma from type 1 diabetic patients was investigated with the goal of finding
improved candidate biomarkers to predict diabetic nephropathy. In order to reach lower concentration proteins in
plasma a pre-fractionation step, either hexapeptide bead-based libraries or anion exchange chromatography, was
performed prior to surface enhanced laser desorption/ionization time-of-flight mass spectrometry analysis.
Results: Proteomic analysis of plasma from a cross-sectional cohort of 123 type 1 diabetic patients previously
diagnosed as normoalbuminuric, microalbuminuric or macroalbuminuric, gave rise to 290 peaks clusters of which
16 were selected as the most promising biomarker candidates based on statistical performance, including
independent component analysis. Four of the peaks that were discovered have been identified as transthyretin,
apolipoprotein A1, apolipoprotein C1 and cystatin C. Several yet unidentified proteins discovered by this novel
approach appear to have more potential as biomarkers for diabetic nephropathy.
Conclusion: These results demonstrate the capacity of proteomic analysis of plasma, by confirming the presence
of known biomarkers as well as revealing new biomarkers for diabetic nephropathy in plasma in type 1 diabetic
patients.
Background
Diabetic nephropathy will affect approximately 30% of
all patients with diabetes [1,2]. The proportion of
patients that progress to end stage renal disease (ESRD)
because of diabetic nephropathy has been estimated to
be 7% [3] and as a consequence diabetic nephropathy is
the most common cause of renal failure in the devel-
oped world [4,5]. Diabetic nephropathy advances
through a number of recognizable steps from sub-clini-
cal disease to the first measurable stage of microalbumi-
nuria (MIC), defined as persistent albumin excretion
levels in urine normalized to creatinine levels (U-albu-
min) of 30-300 mg/24 h, to macroalbuminuria/diabetic
nephropathy (DMN) with U-albumin>300 mg/24 h.
DMN is followed by renal dysfunction and ultimately
ESRD. Although positive effects on the development
and progression of diabetic nephropathy through strict
control of blood glucose [6], blood pressure [7] and in
particular blockade of the renin-angiotensin system [8,9]
have been reported, it still has not been enough to pre-
vent the high incidence of end stage kidney damage
caused by diabetes. Administration of cardiovascular
drugs, which are commonly prescribed for patients with
MIC or DMN, can markedly decrease the urinary albu-
min excretion rate (UAER) without concomitant
improvement of the disease state.
In order for intervention to have optimal effect on
prevention of ESRD, initiation early on in the disease
process is crucial. At present MIC is used as the best
risk marker for development of diabetic nephropathy;
however, the number of patients with MIC that progress
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to DMN is less in recent studies compared to pre-
viously, and some even regress to normoalbuminuria
(N)(U-albumin<30 mg/24 h) [1].
The search for new biomarkers for diabetic nephropa-
thy, with a few exceptions, has focused on either
hypothesis-driven studies or urinary-based proteomics
[10-13]. To date only two studies have investigated the
proteome of blood in search for biomarkers and these
studies were accomplished with sera from patients with
type 2 diabetes (T2D) [14,15]. This study focuses on
analyzing plasma from type 1 diabetic (T1D) patients
because of its advantage in reflecting more general
changes that occur in the human body and because it is
a relatively stable biological fluid that does not require
normalization, as is the case with urine.
The main challenge in plasma proteome research is
that candidate biomarkers are present in trace amounts
among a large background of non-relevant and abun-
dant proteins. A multitude of pre-fractionation techni-
ques has been described [16], but the majority of them
are inherently low throughput and are not compatible
with the analysis of individual patient samples. Bead-
based fractionation methods, on the other hand, offer a
workflow that is amenable to automation and clinical
proteomics workflows. For the present study, two differ-
ent bead-based techniques were chosen for biomarker
discovery: anion exchange and hexapeptide library
resins. Anion exchange is used to separate proteins in
plasma according to their isoelectric points, whereas the
hexapeptide library beads can drastically reduce the
amounts of the most abundant proteins in plasma while
simultaneously enhancing the concentration of the most
dilute species [17]. The techniques were combined with
surface enhanced laser desorption/ionization time-of-
flight mass spectrometry (SELDI-TOF-MS) and inde-
pendent component analysis (ICA) to detect changes in
protein levels between patients with N, MIC and DMN.
Earlier discovery of patients most at risk for developing
diabetic nephropathy could allow early initiation of
intervention and a more tailored management of late
complications in diabetes.
Results
Clinical data
Patient groups in the cross-sectional cohort were
matched with respect to gender, duration of diabetes
and body mass index (BMI) but differed slightly by age
(p = 0.01). The DMN group had significantly lower esti-
mated glomerular filtration rates (eGFR) compared to
the other groups (p < 0.0001) while equivalent eGFR
values were observed in the N and MIC groups. There
were no significant differences in systolic blood pressure
or diastolic blood pressure for comparisons of all groups
or for levels of serum cholesterol between the groups.
Haemoglobin A1c (HbA1c) differed significantly for an
all group comparison (p = 0.02), this was caused by a
significant difference between the N and DMN groups.
The clinical data are summarized in Table 1.
SELDI-TOF-MS
Plasma complexity was reduced prior to proteomic ana-
lysis by anion exchange or hexapeptide fractionation.
Analysis of individual T1D patients resulted in more
than 1000 protein and peptide peaks in the spectra gen-
erated by SELDI-TOF-MS. After spectral processing and
cluster selection, the data for individual peaks were sub-
jected to stringent quality control as a part of feature
Table 1 Clinical data of the diabetic patients differentiated according to level of albuminuria
N MIC DMN p value
n, total 42 40 41
Gender, Male (female) 19 (23) 18 (22) 22 (19) 0.25
Age (years) 56 (11) 55 (11) 49 (10)* 0.01
DM duration (years) 36 (11) 36 (11) 34 (10) 0.58
BMI (kg/m2) 24.5 (2.8) 25.2 (3.7) 25.3 (4.5) 0.62
HbA1c (%) 8.2 (1) 8.8 (1.2) 8.9 (1.1)* 0.02
Creatinine (μmol/l)◆ 91 (82-96) 90 (81-102) 124 (99-172)* ,§ <0.0001
U-albumin (mg/g)◆¶ 6 (4-8) 23 (9-59) 453 (195-936) * ,§ <0.0001
eGFR(ml/min/1.73 m2) 70.1 (10.7) 68.6 (11.4) 49.5 (18.5) * ,§ <0.0001
Cholesterol (mmol/l) 4.8 (0.8) 5 (1) 4.9 (1) 0.55
Systolic BP (mmHg) 138 (23) 140 (23) 144 (19) 0.42
Diastolic BP (mmHg) 74 (10) 73 (12) 78 (10) 0.09
Numbers are presented as mean (SD). ◆ Numbers are presented as median (IQR). ¶ Some patients had U-albumin levels reduced by antihypertensive medication
which was not stopped when spot urine samples were collected for the study.
* Indicates that means differed significantly between DMN group and N group.
§ Indicates that means differed significantly between DMN group and MIC group.
# Indicates that means differed significantly between MIC group and N group.
n, numbers; DM, diabetes mellitus; HbA1c, hemoglobin A1c; U-albumin, urinary albumin levels normalized to creatinine levels; eGFR, estimated glomerular
filtration rate; BP, blood pressure
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reduction, which resulted in a total of 518 peak clusters
(179 from anion exchange and 339 from hexapeptide
studies). The peak data were further reduced prior to
final data analysis to exclude all peaks that were highly
correlated to avoid discovering redundant candidate bio-
markers. The final peak lists included 290 peak clusters
(111 from anion exchange and 179 from hexapeptide
studies).
ICA
One of the challenges in SELDI-TOF-MS profiling, or
other top-down approaches such as matrix assisted laser
desorption time-of-flight mass spectrometry (MALDI-
TOF-MS), is the reduction of false positives that arise
from the nature of the data. Spectra acquired by SELDI-
TOF-MS are complex because they are composed of a
number of peaks, some of which are highly correlated,
that are polluted by noise as well as artefacts of biologi-
cal, chemical or physical origin. One potential solution
to this problem is the application of ICA, which is a sig-
nal processing technique used to separate distinct
underlying signals from mixed recorded signals. The
observed signals are the protein peak clusters, believed
to be independent of each other, and can be charac-
terised as comprised of a mixture of the independent
components (ICs). Components can be evaluated on the
basis of their statistical properties [18]. The ICs that
were capable of separating the groups based on a Krus-
kal-Wallis (KW) test were selected and the peaks that
contributed significantly to the IC were identified by
having a high absolute load value in the component
matrix. Each component was further tested for its stabi-
lity by multiple runs of the algorithm where the mean
of the correlation between the components in the com-
ponent matrix was used as a stability score of the com-
ponent. This was done to ensure robustness and to
avoid finding components defining local maxima, such
as noise or artefacts. All p values were adjusted for
multiple testing by the Benjamini-Hochberg algorithm
[19]. Selection of proteins for future research were
based on two different criteria: either proteins contribut-
ing to components with stability >0.8 and KW p value <
0.0001 or peaks differing significantly between groups
with a KW p value < 0.0001. Tables 2 and 3 list the 16
peaks selected for future investigation.
Identification of candidate biomarkers
Overlap between the two data sets from each fractiona-
tion method is a possibility, but cannot be determined
directly without protein identification, which is not an
integral part of a SELDI-TOF-MS study and can be
extremely time consuming. The two data sets are there-
fore considered as independent of one another. Only
previously established or particularly promising candi-
dates are identified at this stage of biomarker discovery.
Among the highest contributing proteins in the chosen
components and peaks in diabetic nephropathy,
impaired renal function and other diseases were the fol-
lowing: transthyretin, apolipoprotein C1 (apo C1), apoli-
poprotein A1 (apo A1) and cystatin C. The identities of
Table 2 Protein peaks contributing significantly to top ICA components.
Component Stability Score p value Peak(s) (m/z) Protein Identity(ies)
5 0.809212 2.67E-07 13880 Transthyretin*
59 0.801315 3.62E-06 11351
13880
-
Transthyretin*
15 0.85689 9.79E-06 6963.9 -
91 0.807664 3.43E-05 28121
6631.5
Apo A1*
Apo C1**
28 0.807874 4.93E-05 17278 -
34 0.877577 6.02E-05 28111 Apo A1*
95 0.823827 9.07E-05 5684.4
28111
-
Apo A1*
116 0.822404 9.07E-05 8938.3 -
33 0.857141 9.07E-05 17396 -
*Proteins identified by sequencing. **Proteins identified by immunoprecipitation, sequencing and westernblots. m/z, mass to charge. P values are Benjamini-
Hochberg corrected for multiple testing.
Table 3 Proteins selected based on the lowest KW value
in comparison of the three groups.
p value Peak (m/z) Protein Identity
1.12E-06 13584 -
3.13E-06 9101.8 -
3.13-06 28121 Apo A1*
3.64E-06 13350 Cystatin C**
3.64E-06 2956.7 -
9.42E-06 13880 Transthyretin*
1.51E-05 11344 -
6.99E-05 6963.9 -
7.34E-05 9185.4 -
9.73E-05 13797 Transthyretin*
*Proteins identified by sequencing. **Proteins identified by
immunoprecipitation. P values are Benjamini-Hochberg corrected for multiple
testing.
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these proteins were confirmed by immunoprecipitation
and sequencing or western blots. Apo A1 (28111/28121
Da) was observed in three of the components and was
also on the list of proteins chosen based on the p values
from the KW analysis (Table 2 and 3), where the lowest
levels of the protein were found in the DMN group
(Figure 1). Apo C1 (6631.5 Da), a protein related to dia-
betes and diabetic nephropathy was identified as contri-
buting significantly, along with apo A1, in component
91 (Table 2). Furthermore a KW analysis of the differ-
ence in peak intensities between the groups showed that
the means differed significantly between all groups (p =
0.012), with the lowest levels found in the DMN group
(Figure 2). These results were confirmed with western
blotting that verified lower apo C1 levels in the DMN
group compared to the MIC and N groups (Figure 3).
The expression levels of transthyretin (13797/13880 Da)
and cystatin C (13350 Da), two established diabetes or
renal function-related related proteins, were significantly
lower in the DMN group compared to the other groups
(p < 0.0001) but equivalent transthyretin and cystatin C
levels were observed in the N and MIC groups (Figure 4
and 5 respectively).
Reproducibility
The reproducibility of all analyses was followed using
reference standards subjected to the same workflow as
Figure 1 Candidate biomarkers for diabetic nephropathy. (A) Box and whiskers plot of apo A1 intensity, where the three diabetic groups are
divided by albuminuria, the ordinate represents the peak intensity for the marker. (B) SELDI-TOF-MS spectra of known markers of diabetic
nephropathy significantly different between the groups: apo A1, the ordinate is the m/z of the peak, and the abscissa is the relative intensity.
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patient samples. The inter-assay coefficients of variation
(CV) was 23.4% (15.4%-29%) for CM10 arrays and
20.8% (15.2%-28.6%) for Q10 arrays after hexapeptide
fractionation, whereas the CV after anion exchange frac-
tionation was 21.8% (19.1%-27%) for CM10 arrays and
23.7% (19.7%-29.1%) for IMAC30 arrays. Additional file
1; Table S1 describes the main differences and results
obtained with the two different fractionation strategies.
Discussion
The current best predictive marker of future develop-
ment of diabetic nephropathy is MIC in both T1D and
T2D. The development of renal disease from the first
clinical sign of MIC to DMN is characterised by pro-
gressively damaged glomerular capillary wall function
and breakdown of the filtration barrier. The stage of
MIC already represents a measurable level of diabetic
kidney disease where advanced structural renal damage
has occurred and may progress further independent of
metabolic control [20,21]. Although the measurement of
albuminuria is currently the best available non-invasive
method for early detection of pending renal disease in
diabetic patients, much debate exists in the current lit-
erature about its sensitivity and specificity [1]. Urinary
albumin content is influenced by several factors such as
intensive physical activity, the menstrual cycle, infection
of the urinary system, hypertension and other nephropa-
thies [12]. Consequently, new and better biomarkers and
risk predictors are needed.
Lower levels of apo C1 were found in the micro- and
macroalbuminuric groups compared to normoalbuminu-
ric, which differs from what is previously reported [22].
Hirano et al found that apo C1 levels in the very low-
density lipoproteins (VLDL) increased with the growing
Figure 2 Candidate biomarkers for diabetic nephropathy. (A) Box and whiskers plot of apo C1 intensity, where the three diabetic groups are
divided by albuminuria, the ordinate represents the peak intensity for the marker. (B) SELDI-TOF-MS spectra of known markers of diabetic
nephropathy significantly different between the groups: apo C1, the ordinate is the m/z of the peak, and the abscissa is the relative intensity.
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severity of diabetic nephropathy. A possible explanation
could be that our data reflects the total content of apo
C1 in both HDL and VLDL particles in the plasma
whereas Hirano et al measured apo C1 incorporated in
the VLDL particles only.
Furthermore, apo A1, cystatin C and transthyretin
levels were all identified as either contributing signifi-
cantly to components and/or were significantly different
between the groups based on a KW analysis, this is in
accordance to what has previously been described about
these proteins, and it has been proposed that these pro-
teins could have diagnostic value in DMN [23-26]. The
candidate biomarkers discovered in this cross-sectional
cohort may turn out to be progression biomarkers, but
they need to be corroborated in a longitudinal cohort.
The nature of the current cohort, in which the DMN
group had varying degrees of duration, resulted in a
spread in U-albumin values at the time of blood sam-
pling due to antihypertensive treatment of the DMN
and MIC patients. The presence of a standard treatment
in the cohort brings robustness and persistence to the
actually obtained candidate biomarkers and reflects the
everyday clinical setting.
Interestingly, a number of not yet described protein
peaks were identified in this study, probably as a result
of the initial plasma complexity reduction prior to the
SELDI-TOF-MS analysis. The intensity of these candi-
date markers were very different between the groups
and could have future potential in contributing to a
superior model of proteins that are able to predict
nephropathy in diabetic patients. At present we are
working on establishing the identity of these proteins.
Conclusion
In this study we evaluated whether it is possible to dis-
tinguish plasma protein profiles from T1D patients with
various degrees of albuminuria using SELDI-TOF-MS
and bioinformatic tools. ICA identified 16 candidate
peaks that contributed significantly in their respective
components with high stability and ability to separate
the groups. ICA has previously been applied to extract
reliable protein signals from MALDI-TOF-MS spectra,
where the algorithm also was used to detect differences
in protein peaks between experimental groups [27]. The
technique has the potential to considerably increase the
quality of the resulting data and improve the biological
validity of subsequent examination and seems to be a
promising tool for biomarker discovery studies. Future
research is aimed at analysing larger groups of samples.
After establishing a model based on proteomic patterns
for the separation of the three groups, the model will be
validated in longitudinal sample sets to determine the
diagnostic and predictive value of the obtained protein
profiles. It is our goal to find biomarkers able to predict,
detect and monitor the progression of DMN and the
effect of reno- protective intervention in diabetic
patients.
Materials and methods
The Cohort
The participants consisted of Caucasian patients with
T1D examined at Steno Diabetes Center in 2004 and
the samples chosen for the current study were divided
into three groups based on albumin levels in 24 hour
urine collections analysed as part of the routine care: 42
with N (U-albumin < 30 mg/24 h), 40 with MIC (at
least two out of three consecutive urines with albumin
excretion rate 30-300 mg/24 h) and 41 patients with
persistent DMN (U-albumin > 300 mg/24 h). The inter-
val between DMN diagnosis and sample collection of
the cohort was variable. The DMN group was selected
for the previously diagnosed presence of diabetic
nephropathy independent of its duration. The majority
of the group was being treated to reduce their blood
pressure and subsequently, their U-albumin at the time
of sampling was not necessarily representative of disease
progression. At the time of plasma sampling, 26 out of
Figure 3 Western blots of apo C1. (A) The chart represents the
normalized average intensities (SD) of two independent gels of the
same six samples, two from each group of diabetic patients. The
bands intensities where detected by the computer software Multi
Gauge version 2.0 from Fujifilm. (B) On the gel the first two lanes,
from left to right, is two samples from the N group, next two lanes
are two samples from the MIC group, and the last two are from the
DMN group.
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41 patients still had an U-albumin of > 300 mg/day
while 13 had intermediate levels and only two were low-
ered enough to be placed in the N group if they had not
previously been diagnosed. Of the 15 patients whose
levels were lower than at the point of diagnosis, five
were put on a short pause from their antihypertensive
medication and three of them returned to U-albumin
levels above 300 mg/day before resuming their medica-
tion. The two other patients had level increases up to
206 and 291 mg/day, values which approach the cutoff
for DMN, and support the original diagnosis. In a fol-
low-up period four years after sampling there were only
three patients (two from MIC and one from N) who
had progressed to diabetic nephropathy.
Originally, groups were matched by gender, age (± 5
years) and duration of diabetes (± 3 years) (>20 years,
for normoalbuminuric patients). Investigations were
performed in the morning after an overnight fast. Arter-
ial blood pressure was measured three times with an
appropriate cuff size following at least 10 min supine
rest. Urinary albumin concentration was measured by
an enzyme immunoassay from early morning spot urine
collections. Serum and urine creatinine concentration
was assessed by a kinetic Jaffé method [28]. Glomerular
filtration rate was estimated (eGFR) using the 4 variable
MDRD GFR formula (age, gender, race, serum creati-
nine) http://mdrd.com/. Plasma samples were stored at
-80 C until analysis. The study was approved by the
local ethics committee and all patients gave their
informed consent.
Two samples from DMN, two from MIC and one
from N did not contain the adequate volume for the
hexapeptide fractionation and where left out as com-
pared to the anion exchange method.
Figure 4 Candidate biomarkers for diabetic nephropathy. (A) Box and whiskers plot of transthyretin intensity, where the three diabetic
groups are divided by albuminuria, the ordinate represents the peak intensity for the marker. (B) SELDI-TOF-MS spectra of known markers of
diabetic nephropathy significantly different between the groups: transthyretin, the ordinate is the m/z of the peak, and the abscissa is the
relative intensity.
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Plasma Fractionation
The patient plasma samples along with aliquots of refer-
ence human serum which we used to measure reprodu-
cibility, were fractioned in a high through put
automated system by two different techniques: anion
exchange chromatographic Q Ceramic HyperD 20 resin
(Pall, East Hills, New York, USA) and with ProteoMiner
hexapeptide library beads (BioRad, Malvern, Pennsylva-
nia, USA). For the anion exchange chromatography frac-
tionation bulk resin was washed and equilibrated with
50 mM Tris (pH 9) and adjusted to a 50% slurry. Ali-
quots of the resin were dispensed into wells of filter
plates (Nunc, Rochester, New York, USA) and washed
twice with 50 mM Tris (pH 9). Plasma samples from
each patient were centrifuged for 20 min at 10,000 × g
and an aliquot (50 μL) of each was partially denatured
by mixing with 50 μL 9 M urea + 2% CHAPS in 100
mM HEPES (pH 7) for 30 min at 4°C. The plasma sam-
ples were transferred to the equilibrated resin in the fil-
ter plates and incubated with shaking for 30 min at 4°C.
The flow through (Q FT) was collected along with a 100
μL 100 mM HEPES (pH 7.0) + 0.01% OGP wash. A ser-
ies of step-wise elutions (2 × 100 μL) was performed:
100 mM HEPES (pH 7.0) + 0.01% OGP (Q E1), 100
mM Sodium Acetate (pH 5.0) + 0.1% OGP (Q E2), 100
mM Sodium Acetate (pH 4.0) + 0.1% OGP (Q E3) and
3.0 M Guanidine (in 100 mM Sodium Acetate (pH 4.0)
+ 0.1% OGP) (Q E4). The resin was washed with 25/25/
50 Acetonitrile/2-propanol/Water + 0.1% TFA (2 × 100
μL, Q E5).
The fractionation of plasma with hexapeptide beads
was performed using ProteoMiner beads. Plasma was
incubated with the resin as described previously and
proteins where eluted sequentially with the four
Figure 5 Candidate biomarkers for diabetic nephropathy. (A) Box and whiskers plot of cystatin C intensity, where the three diabetic groups
are divided by albuminuria, the ordinate represents the peak intensity for the marker. (B) SELDI-TOF-MS spectra of known markers of diabetic
nephropathy significantly different between the groups: cystatin C, the ordinate is the m/z of the peak, and the abscissa is the relative intensity.
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following solutions: 1 M sodium chloride in 20 mM
HEPES (pH 7.0) (PM F1), 0.2 M Glycine (pH 2.4) (PM
F2), 60% (w/v) ethylene glycol in water (PM F3) and
33.3% (v/v) 2-propanol, 16.7% (v/v) acetonitrile, 0.1% (v/
v) triflouroacetic acid (PM F4).
Preparation of SELDI-TOF-MS Arrays
The plasma fractions from both preparation techniques,
with the exception of Q E5 and the flow through (PM
FT) from the ProteoMiner preparation were analyzed by
SELDI-TOF-MS. The fractions from the anion exchange
preparation were analyzed on cation exchange (CM10),
and in some cases, immobilized metal affinity (IMAC30)
arrays. The ProteoMiner fractions were all analyzed on
CM10 arrays with the addition of strong anion exchange
(Q10) arrays on PM F2 and PM F3. The IMAC30 arrays
were charged with copper (Q E1) or nickel (Q FT, Q E2
and Q E3). The arrays were prepared as described pre-
viously [29,30]. Sinapinic acid was used as the matrix
for all array preparations. The arrays were prepared
using an automated system and read in a PCS-4000
instrument (Bio-Rad, Malvern, Pennsylvania, USA) with
a high and a low laser setting. Detailed protocols on
data acquisition and data processing are listed as supple-
mentary information in additional file 2.
Statistical Analysis
The clinical data was evaluated using the GraphPad
Prism statistical software. All group comparisons where
done by a one-way ANOVA followed by a Tukey post-
test, and the individual group comparisons by a stu-
dent’s t-test. For non-ordinal data, a KW test followed
by a Dunns post-test, where used for all group compari-
son and a Mann-Whitney test for evaluation of the indi-
vidual groups in between.
Statistical calculations of the proteomics data were
performed using the R software environment http://
www.r-project.org. The analysis of the data from the
anion exchange fractionation was done in a two stage
process. In the first stage all two group comparisons
were performed using the student’s t-test. The three dia-
betic groups were analyzed using an analysis of variance
(ANOVA) p value derived from a linear model. Two
comparisons were employed for feature reduction: p
values derived from the comparison of the N/DMN
groups and the ANOVA for all three diabetic groups.
All peak clusters with a p value of ≤ 0.01 (223 for the
student’s t-test and 187 for the ANOVA test) were con-
sidered for further analysis. The t-test had a statistical
power of 0.97 (n = 42 (per group), a = 0.01) while the
ANOVA had a statistical power of 0.99 (n = 42 (per
group), a = 0.01, between group variance = 1, within
group variance = 3).
A more precise cluster alignment was achieved by per-
forming an internal mass calibration using the average
mass for a cluster for which a peak appeared in every
single spectrum. This method allowed for an improved
alignment using peaks that are common to all spectra
and does not rely on previous knowledge of a peak’s
identity. The peaks selected in the first stage were
manually relabeled in the aligned spectra. All peaks not
deemed to be true peaks were excluded from further
analysis. A total of 179 peak clusters were carried
forward.
The data structure complexity and redundancy was
reduced by identifying peak families (Spearman correla-
tion coefficient ≥ 0.85) and retaining only the most
intense member. Both a KW test with a Benjamini-
Hochberg correction for multiple testing and ICA were
performed on the remaining 111 peak clusters. ICA was
performed using 100 components and run a total of five
times. The results from each run were tested for stabi-
lity by comparing the results with a set of 100 indepen-
dent runs. Only components with a stability score (min.
- max., 0 - 1.0) of ≥ 0.80 were retained. The perfor-
mance of each component was tested using a KW test
with a Benjamini-Hochberg correction for multiple
testing.
The spectra obtained from the hexapeptide fractiona-
tion of plasma were initially internally calibrated by
cluster alignment as mentioned above before statistical
analysis in a two stage process. In the first stage all two
group comparisons were performed using a Mann-
Whitney U test, and the three diabetic groups were
additionally compared using a KW test. Two conditions
were employed for feature reduction: p values ≤ 0.05
derived from the comparison of the N/MA groups and
p values ≤ 0.05 acquired from the comparison of the
three diabetic groups by the KW test.
Based on the data from the Q fractionation, we esti-
mate that at 95% power at a significance level of 0.05
group differences will be significant assuming a within
group variance of 0.69. The comparisons can detect dif-
ferences between groups using 28 or more participants.
In the second stage all peak clusters selected were
manually relabeled and all peaks not judged to be true
peaks were excluded from further analysis. A total of
339 peak clusters were retained. The data was analyzed
identically as for the anion exchange fractionation with
the difference that each of the fractions from the hexa-
peptide bead treatment were considered independent of
one another and were carried forward separately (179
peak clusters). ICA was performed using 117
components.
Immunoprecipitation
The identities of cystatin C, transthyretin, apo C1 and
apo A1 were confirmed using Dynabeads protein-G
beads (Invitrogen, Carlsbad, California, USA) and speci-
fic antibodies (Dako, Carpinteria, California, USA or
Abcam, Cambridge, Massachusetts, USA). The unbound
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sample and the eluted protein was analyzed on SELDI-
TOF-MS to confirm depletion elution of the right peak.
Additionally, the eluted protein was trypsin digested and
analyzed on ESI ion trap MS. Detailed protocols for the
immunoprecipitation and trypsin digestion are listed in
the supplementary information in additional file 2. The
identities of the digested proteins were identified based
on matching the MS/MS data with mass values calcu-
lated for selected ion series of a peptide. A protein data-
base was searched without applying any constraints on
molecular weight or species by Mascot (Matrix Science
Inc., Boston, Massachusetts, USA) [31]. Transthyretin
and apo A1 were identified with several peptide
matches, but apo C1 was identified on the basis of a sin-
gle peptide. The amino acid sequences were blasted and
identified by Mascot and the identification approved if
the score of the peptides where equal or exceeded the
score reported by mascot to be significant as previously
described [31].
Detection and quantification of Apo C1 by Western blots
As prove of concept of the semi quantitative abilities of
SELDI-TOF-MS and to confirm the identity of apo C1
we performed western blots. Protocols for western blots
are listed in supplementary information in additional file
2.
Supplementary information is available at Proteome
Science’s website.
Additional file 1: Supplementary Table. SELDI-TOF-MS analysis of the
two different fractionation techniques.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1477-5956-8-4-
S1.DOC ]
Additional file 2: Supplementary information. Detailed protocols of
data acquisition and processing, immunoprecipitation, trypsin digestion
and western blotting.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1477-5956-8-4-
S2.DOC ]
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